New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2014
10:01 EDTMTD, SNAK, TMO, OMED, VSTM, HLT, AHP, TOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AT&T (T) initiated with a Buy at Drexel Hamilton... Ashford Hospitality Prime (AHP) initiated with a Buy at SunTrust... Cypress Energy (CELP) initiated with an Outperform at Raymond James... Hilton Worldwide (HLT) initiated with a Positive at Susquehanna... OncoMed (OMED) initiated with a Buy at Mizuho... RSP Permian (RSPP) initiated with an Overweight at Barclays... The Inventure Group (SNAK) initiated with an Outperform at Wedbush... Verastem (VSTM) initiated with a Buy at Mizuho... Xilinx (XLNX) initiated with a Buy at MKM Partners... RSP Permian (RSPP) initiated with an Outperform at Raymond James... Thermo Fisher (TMO) resumed with an Overweight at JPMorgan... Mettler-Toledo (MTD) initiated with a Market Perform at Wells Fargo.
News For T;AHP;HLT;OMED;SNAK;VSTM;TMO;MTD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
January 20, 2015
16:04 EDTVSTMVerastem files to sell $40M in common stock
Subscribe for More Information
08:04 EDTVSTMVerastem receives orphan medicinial product designation from EC for VS-5584
Subscribe for More Information
07:05 EDTVSTMVerastem doses first patient in Phase 1 VS-5584 trial
Subscribe for More Information
06:24 EDTTT-Mobile warns of unsustainable costs against cellphone giants, Re/code says
T-Mobile (TMUS) owner Deutsche Telekom (DTEGY) claims Verizon (VZ) and AT&T's (T) wealth makes true competition difficult, reports Re/code, citing statements made at Germany's DLD conference. Deutsche Telekom CEO Tim Hoettges stated the dominance of AT&T and Verizon allowed them to make huge bids at the latest midband spectrum auction to further their market lead. Hoettges also stated he was "intrigued" by last year's unsuccessful merger talks with Sprint (S), and warned that T-Mobile's $4B-$5B investment requirements per year are unsustainable. Reference Link
January 18, 2015
13:45 EDTTGoogle in talks to acquire mobile-pay platform Softcard, WSJ says
Subscribe for More Information
January 16, 2015
18:07 EDTTCongressional GOP unveil net neutrality law to bypass FCC, LA Times reports
Representatives Fred Upton of Michigan and John Thune of South Dakota endorsed a congressional bill that would protect net-neutrality by banning internet service providers from charging companies extra to load their sites, and prohibit broadband companies from blocking legitimate websites, or slowing speeds for customers, superseding the FCC's authority to regulate the internet, according to the LA Times. Major internet companies such as AT&T (T) , Comcast (CMCSA), and Verizon Communications (VZ) have opposed a recent recommendation by FCC Chairman Thomas Wheeler to treat internet service similar to a utility. Reference Link
17:25 EDTTAT&T reports Q4 $10B charge related to pension benefits and network assets
For the quarter ended December 31, AT&T expects to record a noncash, pre-tax loss of approximately $7.9B related to actuarial gains and losses on pension and postemployment benefit plans. At December 31, the company decreased its assumed discount rates used to measure the pension obligation to 4.3% and to 4.2% for the company's postretirement obligation. These reductions resulted in an actuarial loss of approximately $7.9B. Also contributing to the amount were losses due to updated mortality assumptions offset by asset gains in excess of its assumed rate of return as well as demographic changes and other assumptions. Actuarial gains and losses are managed on a total company basis and are, accordingly, reflected only in consolidated results. Therefore, this loss will not affect segment operating results or margins. The company's Q4 operating results will also include a $2.1B noncash charge for the abandonment in place of certain network assets. During Q4, the company performed an analysis of its network assets and determined that specific copper assets will not be necessary to support future network activity, due to declining customer demand for AT&T's legacy voice and data products and the migration of its networks to next generation technology. This decision by management will not be considered in the company's assessment of segment performance and therefore, this charge will be reflected only in consolidated results and will not affect segment operating results or margins.
14:33 EDTOMEDOncoMed presents final Phase 1b data for Tarextumab
OncoMed Pharmaceuticals presented final safety, efficacy and biomarker data from the company's Phase 1b "ALPINE" clinical trial of tarextumab in 40 patients with frontline metastatic pancreatic cancer. Tarextumab was generally well tolerated when administered with gemcitabine and Abraxane, with manageable, on-target drug-related toxicities. The Phase 2 dose of tarextumab was determined to be 15 mg/kg every two weeks in combination with the standard-of-care. Among patients evaluable for response using RECIST criteria, 38% achieved partial responses, with an additional 35% achieving stable disease for an overall clinical benefit rate of 73%. Median progression-free survival and overall survival values for the three drug combination of tarextumab-gemcitabine-Abraxane were 5.6 months and 11.6 months, respectively, for all patients treated with the three-drug combination. The data presented included biomarker analyses that showed that among patients whose tumor samples had elevated levels of Notch3 gene expression, trends toward higher response rates and longer survival were noted, as compared to patients with low Notch3 expression. Median PFS and OS for patients with high Notch 3 expression were 6.6 months and 14.6 months, respectively. Given the small sample size and potential imbalances in patient characteristics, these encouraging preliminary efficacy and predictive biomarker observations are being assessed in the ongoing randomized, placebo-controlled, Phase 2 ALPINE trial
10:06 EDTAHPBofA/Merrill real estate analysts to hold an analyst/industry conference call
U.S. Real Estate Analyst Spector, along with EMEA Real State Analyst Bessell, HK/China Real Estate Analyst Ngai and ASEAN Real Estate Analyst Chua, discuss key trends in Global Property/Real Estate in 2015 on an Analyst/Industry conference call to be held on January 20 at 8 am.
10:01 EDTAHPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:37 EDTAHPAshford Hospitality Prime downgraded to Underperform from Buy at BofA/Merrill
Subscribe for More Information
07:03 EDTVSTMVerastem announces publication of scientific data for VS-5584 in cancer research
Verastem announced that a paper, titled “PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells,” has been published in Cancer Research, a peer-reviewed journal of the American Association for Cancer Research. The paper discusses results from preclinical research evaluating VS-5584, a highly potent, selective small molecule inhibitor of mTORC1/2 and Class I PI3K kinases, which preferentially targets cancer stem cells in vitro and in vivo. CSCs represent a subpopulation of cancer cells that have tumor-initiating capability, are particularly resistant to chemotherapy and can mediate tumor recurrence both locally and at metastatic sites. The study results demonstrated that VS-5584 is up to 30-fold more potent in inhibiting the proliferation and survival of CSCs compared to non-CSCs in solid tumor cell populations. VS-5584 preferentially diminished CSC levels in multiple mouse xenograft models of human cancer. Similarly, VS-5584 treatment ex vivo preferentially reduced CSCs in surgically resected breast and ovarian patient tumors. In contrast, chemotherapeutics such as paclitaxel, cisplatin and etoposide effectively targeted bulk tumor cells, but enriched CSCs. Mechanistic investigations revealed that knock down of PI3Kα, PI3Kβ or mTOR alone was insufficient to decrease CSCs, while knock down of PI3Kα, PI3Kβ and mTOR together effectively reduced CSCs mimicking the effect of VS-5584. Consistent with CSC ablation, VS-5584 delayed tumor regrowth following chemotherapy in xenograft models of small cell lung cancer. These data help to elucidate the mechanism of VS-5584 targeting CSCs and provide a strong rationale for the clinical development of VS-5584 in combination with chemotherapeutic agents targeting bulk tumor cells to achieve more durable clinical responses in cancer patients.
05:39 EDTVSTMVerastem risk/reward favorable after pullback, says Mizuho
Subscribe for More Information
January 15, 2015
09:30 EDTMTDMettler-Toledo confirms foreign currency hedges
Mettler-Toledo confirmed it has foreign currency forward contracts that reduce approximately 90% of its exposure from the Swiss franc strengthening against the euro in 2015 and contracts that reduce approximately 70% of its exposure in 2016.
08:36 EDTOMEDOncoMed enrolls first biomarker-selected patient in Notch1 antibody Phase trial
Subscribe for More Information
06:27 EDTTIntel to partner with more IT players for Internet of Things, DigiTimes reports
Intel (INTC) is preparing to team up with more IT firms such as AT&T (T), Verizon (VZ), Cisco (CSCO), SAP (SAP), and Microsoft (MSFT) in order to expand the Internet of Things industry in 2015, reports DigiTimes. According to sources from the upstream supply chain, Intel has been playing an active role in helping Taiwan build its smart city infrastructure and has also cooperated with Chunghwa Telecom to develop the IoT and cloud computing applications. Reference Link
05:55 EDTVSTMVerastem has meeting hosted by Philadelphia Securities Association
Luncheon Meeting to be held in Philadelphia at 11:30 am on January 15 hosted by Philadelphia Securities Association.
January 14, 2015
08:22 EDTTMKM Partners unable to recommend ADTRAN until clarity on AT&T timing
Subscribe for More Information
07:37 EDTMTDJPMorgan to hold a conference
Subscribe for More Information
05:57 EDTHLTLodging sector downgraded to Market Weight at Wells Fargo
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use